Recognizing and correcting failures in glioblastoma treatment

Ashish H. Shah, Regina M Graham, Amade Bregy, Michael Thambuswamy, Ricardo J Komotar

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

While current treatment remains universal for glioblastoma, recent evidence has demonstrated marked heterogeneity in their molecular profiles. Due to the near universal rate of recurrence, attention has focused on individualized treatment and subgroup population differences that may influence the efficacy of adjuvant therapy. Recent studies have implicated chemo-radioresistant GBM stem cells (GSCs) in the propagation of heterogeneous tumor profiles. As a result, there has been a shift to classify and target GSCs in order to increase survival and delay relapse. The overall objective of our editorial is to highlight current failures in GBM treatment and to propose novel personalized methods to correct our shortcomings in GBM treatment.

Original languageEnglish
Pages (from-to)299-302
Number of pages4
JournalCancer Investigation
Volume32
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Glioblastoma
Stem Cells
Recurrence
Population
Neoplasms
Therapeutics

Keywords

  • Editorial
  • Glioblastoma
  • Treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Recognizing and correcting failures in glioblastoma treatment. / Shah, Ashish H.; Graham, Regina M; Bregy, Amade; Thambuswamy, Michael; Komotar, Ricardo J.

In: Cancer Investigation, Vol. 32, No. 6, 01.01.2014, p. 299-302.

Research output: Contribution to journalArticle

Shah, Ashish H. ; Graham, Regina M ; Bregy, Amade ; Thambuswamy, Michael ; Komotar, Ricardo J. / Recognizing and correcting failures in glioblastoma treatment. In: Cancer Investigation. 2014 ; Vol. 32, No. 6. pp. 299-302.
@article{e42e5cf309034985bdda7a92657be2a8,
title = "Recognizing and correcting failures in glioblastoma treatment",
abstract = "While current treatment remains universal for glioblastoma, recent evidence has demonstrated marked heterogeneity in their molecular profiles. Due to the near universal rate of recurrence, attention has focused on individualized treatment and subgroup population differences that may influence the efficacy of adjuvant therapy. Recent studies have implicated chemo-radioresistant GBM stem cells (GSCs) in the propagation of heterogeneous tumor profiles. As a result, there has been a shift to classify and target GSCs in order to increase survival and delay relapse. The overall objective of our editorial is to highlight current failures in GBM treatment and to propose novel personalized methods to correct our shortcomings in GBM treatment.",
keywords = "Editorial, Glioblastoma, Treatment",
author = "Shah, {Ashish H.} and Graham, {Regina M} and Amade Bregy and Michael Thambuswamy and Komotar, {Ricardo J}",
year = "2014",
month = "1",
day = "1",
doi = "10.3109/07357907.2014.909827",
language = "English",
volume = "32",
pages = "299--302",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Recognizing and correcting failures in glioblastoma treatment

AU - Shah, Ashish H.

AU - Graham, Regina M

AU - Bregy, Amade

AU - Thambuswamy, Michael

AU - Komotar, Ricardo J

PY - 2014/1/1

Y1 - 2014/1/1

N2 - While current treatment remains universal for glioblastoma, recent evidence has demonstrated marked heterogeneity in their molecular profiles. Due to the near universal rate of recurrence, attention has focused on individualized treatment and subgroup population differences that may influence the efficacy of adjuvant therapy. Recent studies have implicated chemo-radioresistant GBM stem cells (GSCs) in the propagation of heterogeneous tumor profiles. As a result, there has been a shift to classify and target GSCs in order to increase survival and delay relapse. The overall objective of our editorial is to highlight current failures in GBM treatment and to propose novel personalized methods to correct our shortcomings in GBM treatment.

AB - While current treatment remains universal for glioblastoma, recent evidence has demonstrated marked heterogeneity in their molecular profiles. Due to the near universal rate of recurrence, attention has focused on individualized treatment and subgroup population differences that may influence the efficacy of adjuvant therapy. Recent studies have implicated chemo-radioresistant GBM stem cells (GSCs) in the propagation of heterogeneous tumor profiles. As a result, there has been a shift to classify and target GSCs in order to increase survival and delay relapse. The overall objective of our editorial is to highlight current failures in GBM treatment and to propose novel personalized methods to correct our shortcomings in GBM treatment.

KW - Editorial

KW - Glioblastoma

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84902170312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902170312&partnerID=8YFLogxK

U2 - 10.3109/07357907.2014.909827

DO - 10.3109/07357907.2014.909827

M3 - Article

C2 - 24766304

AN - SCOPUS:84902170312

VL - 32

SP - 299

EP - 302

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 6

ER -